ERBB2 and breast cancer: Although no toxicity has been demonstrated with these plant-expressed biologics per se the ability to raise a strong polyclonal antibody response against Her2 raises the question of potential cardiotoxicity which has been documented with trastuzumab treatment in patients with Her2 positive breast cancer.50